Kura Oncology (KURA) said Tuesday it submitted a new drug application to the US Food and Drug Administration for ziftomenib to potentially treat adults with relapsed or refractory acute myeloid leukemia with an NPM1 mutation.
The biotechnology company said the FDA has 60 days to determine if the NDA is complete and accepted for review. Kura has requested priority review, which, if granted, would set a six-month review timeline after acceptance, the company said.
Kura said ziftomenib has received breakthrough therapy, fast track and orphan drug designations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.